06826.HK
Shanghai Haohai Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 15.63
−2.68%Year over year
Reported trailing growth
- Revenue
- -9.9%
- EBITDA
- -80.0%
- EBIT
- +57.9%
- EPS
- -71.8%
- Free cash flow
- -34.9%
- Operating cash flow
- -24.9%
Forward estimates
Based on analyst estimates
- Revenue
- -36.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- -0.1%
- EBIT
- +12.5%
- Net income
- +10.7%
- EPS
- +1.3%
- Free cash flow
- +10.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026